RxDoctor Payments Data

Amito Chandiwal, MD

Internal Medicine · Houston, TXNPI 1295978393

Payments from drug & device makers

$424in general payments, 2019–2025

Across 27 payments — averaging $15.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$98
  • Pfizer$53
  • AstraZeneca$43
  • Novo Nordisk$41
  • AbbVie$33
  • Lilly USA, LLC$30
  • plus $126 from 7 others

What the payments were for

  • Food & beverage$424100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$424 in reported general payments places this provider in the 55th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$411,058
Medicare patients
999
Services billed
4,007

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban45$49,888
FarxigaDapagliflozin Propanediol39$36,205
OzempicSemaglutide15$30,090
JardianceEmpagliflozin20$24,126
JanuviaSitagliptin Phosphate21$21,199
XareltoRivaroxaban11$17,286
Tresiba Flextouch U-200Insulin Degludec12$10,012
VascepaIcosapent Ethyl11$5,803
Incruse ElliptaUmeclidinium Bromide12$4,279
Gabapentin60$1,621
Tamsulosin Hcl70$1,448
Pantoprazole Sodium91$1,213
Levothyroxine Sodium124$1,199
Albuterol Sulfate HfaAlbuterol Sulfate20$1,093
Rosuvastatin Calcium94$1,011

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$53$49,88845 claims
AstraZenecaFarxiga$43$36,20539 claims
Novo NordiskOzempic$41$30,09015 claims
Boehringer IngelheimJardiance$15$24,12620 claims
MerckJanuvia$13$21,19921 claims
Johnson & JohnsonXarelto$98$17,28611 claims
AbbVieSynthroid$33$73516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →